Abstract
Glutamate is an amino acid that functions as an excitatory neurotransmitter. It has also been associated with somatic and psychiatric distress and is implicated in the pathophysiology of psychiatric disorders such as schizophrenia. Ingestion of dietary glutamate, such as monosodium glutamate (MSG), has been mechanistically linked with greater distress among patients with chronic pain conditions, though findings have been equivocal. Preliminary research suggests that an MSG-restricted diet confers beneficial effects on somatic symptoms and well-being for some individuals with chronic pain conditions. In addition to associations with somatic distress, glutamate has been associated with the onset and progression of psychiatric symptoms. Thus, the role of dietary glutamate in psychiatric distress represents an underdeveloped and potentially important area for future research aimed at clarifying pathophysiological mechanisms and identifying targets for dietary intervention in psychiatric illnesses.
References
1.
Cairns
BE
. Influence of pro-algesic foods on chronic pain conditions
. Expert Rev Neurother
. 2016
;16
(4
):415
–23
.
[PubMed]
1473-71752.
Graybeal
C
, Kiselycznyk
C
, Holmes
A
. Stress-Induced Deficits in Cognition and Emotionality: A Role for Glutamate
. Berlin, Heidelberg
: Springer
; 2011
. pp. 189
–207
. 3.
Coyle
JT
. The glutamatergic dysfunction hypothesis for schizophrenia
. Harv Rev Psychiatry
. 1996
Jan-Feb
;3
(5
):241
–53
.
[PubMed]
1067-32294.
Carlson
LE
, Speca
M
, Patel
KD
, Goodey
E
. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients
. Psychoneuroendocrinology
. 2004
May
;29
(4
):448
–74
.
[PubMed]
0306-45305.
Sanacora
G
, Treccani
G
, Popoli
M
. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders
. Neuropharmacology
. 2012
Jan
;62
(1
):63
–77
.
[PubMed]
0028-39086.
Freeman
M
. Reconsidering the effects of monosodium glutamate: a literature review
. J Am Acad Nurse Pract
. 2006
Oct
;18
(10
):482
–6
.
[PubMed]
1041-29727.
8.
US Food and Drug Administration
. Questions and Answers on Monosodium glutamate
. MSG
; 2012
.9.
Appaiah
KM
. Monosodium Glutamate in Foods and its Biological Effects. Ensuring Global Food Safety
. Elsevier
; 2010
. pp. 217
–26
. 10.
Stegink
LD
, Filer
LJ
Jr, Baker
GL
. Plasma amino acid concentrations in normal adults fed meals with added monosodium L-glutamate and aspartame
. J Nutr
. 1983
Sep
;113
(9
):1851
–60
.
[PubMed]
0022-316611.
Löliger
J
. Function and importance of glutamate for savory foods
. J Nutr
. 2000
Apr
;130
(4S
Suppl
):915S
–20S
.
[PubMed]
0022-316612.
He
K
, Du
S
, Xun
P
, Sharma
S
, Wang
H
, Zhai
F
, et al. Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China Health and Nutrition Survey (CHNS)
. Am J Clin Nutr
. 2011
Jun
;93
(6
):1328
–36
.
[PubMed]
0002-916513.
Geha
RS
, Beiser
A
, Ren
C
, Patterson
R
, Greenberger
PA
, Grammer
LC
, et al. Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study
. J Nutr
. 2000
Apr
;130
(4S
Suppl
):1058S
–62S
.
[PubMed]
0022-316614.
Nelson
LM
, Matkin
C
, Longstreth
WT
Jr, McGuire
V
. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet
. Am J Epidemiol
. 2000
Jan
;151
(2
):164
–73
.
[PubMed]
0002-926215.
Beyreuther
K
, Biesalski
HK
, Fernstrom
JD
, Grimm
P
, Hammes
WP
, Heinemann
U
, et al. Consensus meeting: monosodium glutamate - an update
. Eur J Clin Nutr
. 2007
Mar
;61
(3
):304
–13
.
[PubMed]
0954-300716.
Collison
KS
, Maqbool
Z
, Saleh
SM
, Inglis
A
, Makhoul
NJ
, Bakheet
R
, et al. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease
. J Lipid Res
. 2009
Aug
;50
(8
):1521
–37
.
[PubMed]
0022-227517.
Graham
TE
, Sgro
V
, Friars
D
, Gibala
MJ
. Glutamate ingestion: the plasma and muscle free amino acid pools of resting humans
. Am J Physiol Endocrinol Metab
. 2000
Jan
;278
(1
):E83
–9
.
[PubMed]
0193-184918.
Shimada
A
, Cairns
BE
, Vad
N
, Ulriksen
K
, Pedersen
AM
, Svensson
P
, et al. Headache and mechanical sensitization of human pericranial muscles after repeated intake of monosodium glutamate (MSG)
. J Headache Pain
. 2013
Jan
;14
(1
):2
.
[PubMed]
1129-236919.
Gussew
A
, Rzanny
R
, Erdtel
M
, Scholle
HC
, Kaiser
WA
, Mentzel
HJ
, et al. Time-resolved functional 1H MR spectroscopic detection of glutamate concentration changes in the brain during acute heat pain stimulation
. Neuroimage
. 2010
Jan
;49
(2
):1895
–902
.
[PubMed]
1053-811920.
Mullins
PG
, Rowland
LM
, Jung
RE
, Sibbitt
WL
Jr. A novel technique to study the brain’s response to pain: proton magnetic resonance spectroscopy
. Neuroimage
. 2005
Jun
;26
(2
):642
–6
.
[PubMed]
1053-811921.
Burrin
DG
, Janeczko
MJ
, Stoll
B
. Emerging Aspects of Dietary Glutamate Metabolism in the Developing Gut
. Volume 17
. 2008
.22.
Cananzi
AR
, D’Andrea
G
, Perini
F
, Zamberlan
F
, Welch
KM
. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura
. Cephalalgia
. 1995
Apr
;15
(2
):132
–5
.
[PubMed]
0333-102423.
Ferrari
A
, Spaccapelo
L
, Pinetti
D
, Tacchi
R
, Bertolini
A
. Effective prophylactic treatments of migraine lower plasma glutamate levels
. Cephalalgia
. 2009
Apr
;29
(4
):423
–9
.
[PubMed]
0333-102424.
Peres
MF
, Zukerman
E
, Senne Soares
CA
, Alonso
EO
, Santos
BF
, Faulhaber
MH
. Cerebrospinal fluid glutamate levels in chronic migraine
. Cephalalgia
. 2004
Sep
;24
(9
):735
–9
.
[PubMed]
0333-102425.
Ito
T
, Tanaka-Mizuno
S
, Iwashita
N
, Tooyama
I
, Shiino
A
, Miura
K
, et al. Proton magnetic resonance spectroscopy assessment of metabolite status of the anterior cingulate cortex in chronic pain patients and healthy controls
. J Pain Res
. 2017
Jan
;10
:287
–93
.
[PubMed]
1178-709026.
Harfeldt
K
, Alexander
L
, Lam
J
, Månsson
S
, Westergren
H
, Svensson
P
, et al. Spectroscopic differences in posterior insula in patients with chronic temporomandibular pain
. Scand J Pain
. 2018
Jul
;18
(3
):351
–61
.
[PubMed]
1877-886027.
Smith
JD
, Terpening
CM
, Schmidt
SO
, Gums
JG
. Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins
. Ann Pharmacother
. 2001
Jun
;35
(6
):702
–6
.
[PubMed]
1060-028028.
Holton
KF
, Taren
DL
, Thomson
CA
, Bennett
RM
, Jones
KD
. The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms
. Clin Exp Rheumatol
. 2012
Nov-Dec
;30
(6
Suppl 74
):10
–7
.
[PubMed]
0392-856X29.
Vellisca
MY
, Latorre
JI
. Monosodium glutamate and aspartame in perceived pain in fibromyalgia
. Rheumatol Int
. 2014
Jul
;34
(7
):1011
–3
.
[PubMed]
0172-817230.
Bair
MJ
, Robinson
RL
, Katon
W
, Kroenke
K
. Depression and pain comorbidity: a literature review
. Arch Intern Med
. 2003
Nov
;163
(20
):2433
–45
.
[PubMed]
0003-992631.
Chiappelli
J
, Rowland
LM
, Notarangelo
FM
, Wijtenburg
SA
, Thomas
MA
, Pocivavsek
A
, et al. Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia
. Neuropsychopharmacology
. 2018
Jul
;43
(8
):1706
–11
.
[PubMed]
0893-133X32.
American Psychiatric Association
. Diagnostic and Statistical Manual of Mental Disorders
. American Psychiatric Association
; 2013
. 33.
Javitt
DC
. Glutamate as a therapeutic target in psychiatric disorders
. Mol Psychiatry
. 2004
Nov
;9
(11
):984
–97
.
[PubMed]
1359-418434.
Moghaddam
B
. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia
. J Neurochem
. 1993
May
;60
(5
):1650
–7
.
[PubMed]
0022-304235.
Krystal
JH
, Karper
LP
, Seibyl
JP
, Freeman
GK
, Delaney
R
, Bremner
JD
, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
. Arch Gen Psychiatry
. 1994
Mar
;51
(3
):199
–214
.
[PubMed]
0003-990X36.
Duncan
EJ
, Madonick
SH
, Parwani
A
, Angrist
B
, Rajan
R
, Chakravorty
S
, et al. Clinical and sensorimotor gating effects of ketamine in normals
. Neuropsychopharmacology
. 2001
Jul
;25
(1
):72
–83
.
[PubMed]
0893-133X37.
Krystal
JH
, Karper
LP
, Bennett
A
, D’Souza
DC
, Abi-Dargham
A
, Morrissey
K
, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
. Psychopharmacology (Berl)
. 1998
Feb
;135
(3
):213
–29
.
[PubMed]
0033-315838.
Lancaster
CL
, Teeters
JB
, Gros
DF
, Back
SE
. Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment
. J Clin Med
. 2016
Nov
;5
(11
):E105
.
[PubMed]
2077-038339.
van der Meulen
JA
, Bilbija
L
, Joosten
RN
, de Bruin
JP
, Feenstra
MG
. The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats
. Neuroreport
. 2003
Dec
;14
(17
):2225
–8
.
[PubMed]
0959-496540.
Bohn
I
, Giertler
C
, Hauber
W
. NMDA receptors in the rat orbital prefrontal cortex are involved in guidance of instrumental behaviour under reversal conditions
. Cereb Cortex
. 2003
Sep
;13
(9
):968
–76
.
[PubMed]
1047-321141.
Schuster
GM
, Schmidt
WJ
. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task
. Eur J Pharmacol
. 1992
Nov
;224
(1
):97
–8
.
[PubMed]
0014-299942.
Heresco-Levy
U
, Kremer
I
, Javitt
DC
, Goichman
R
, Reshef
A
, Blanaru
M
, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
. Int J Neuropsychopharmacol
. 2002
Dec
;5
(4
):301
–7
.
[PubMed]
1461-145743.
Pittenger
C
, Bloch
MH
, Williams
K
. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment
. Pharmacol Ther
. 2011
Dec
;132
(3
):314
–32
.
[PubMed]
0163-725844.
Chakrabarty
K
, Bhattacharyya
S
, Christopher
R
, Khanna
S
. Glutamatergic dysfunction in OCD
. Neuropsychopharmacology
. 2005
Sep
;30
(9
):1735
–40
.
[PubMed]
0893-133X45.
Bhattacharyya
S
, Khanna
S
, Chakrabarty
K
, Mahadevan
A
, Christopher
R
, Shankar
SK
. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder
. Neuropsychopharmacology
. 2009
Nov
;34
(12
):2489
–96
.
[PubMed]
0893-133X46.
Brennan
BP
, Rauch
SL
, Jensen
JE
, Pope
HG
Jr. A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder
. Biol Psychiatry
. 2013
Jan
;73
(1
):24
–31
.
[PubMed]
0006-322347.
Pittenger
C
. Glutamatergic agents for OCD and related disorders
. Curr Treat Options Psychiatry
. 2015
Sep
;2
(3
):271
–83
.
[PubMed]
2196-306148.
Sanacora
G
, Zarate
CA
, Krystal
JH
, Manji
HK
, Manji
HK
. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
. Nat Rev Drug Discov
. 2008
May
;7
(5
):426
–37
.
[PubMed]
1474-177649.
Eastwood
SL
, Harrison
PJ
. Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder
. Biol Psychiatry
. 2010
Jun
;67
(11
):1010
–6
.
[PubMed]
0006-322350.
Ongür
D
, Jensen
JE
, Prescot
AP
, Stork
C
, Lundy
M
, Cohen
BM
, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania
. Biol Psychiatry
. 2008
Oct
;64
(8
):718
–26
.
[PubMed]
0006-322351.
Frye
MA
, Watzl
J
, Banakar
S
, O’Neill
J
, Mintz
J
, Davanzo
P
, et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression
. Neuropsychopharmacology
. 2007
Dec
;32
(12
):2490
–9
.
[PubMed]
0893-133X52.
Colla
M
, Schubert
F
, Bubner
M
, Heidenreich
JO
, Bajbouj
M
, Seifert
F
, et al. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol
. Mol Psychiatry
. 2009
Jul
;14
(7
):696
–704
.
[PubMed]
1359-418453.
Yüksel
C
, Öngür
D
. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders
. Biol Psychiatry
. 2010
Nov
;68
(9
):785
–94
.
[PubMed]
0006-322354.
Anis
NA
, Berry
SC
, Burton
NR
, Lodge
D
. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
. Br J Pharmacol
. 1983
Jun
;79
(2
):565
–75
.
[PubMed]
0007-118855.
Moghaddam
B
, Adams
B
, Verma
A
, Daly
D
. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
. J Neurosci
. 1997
Apr
;17
(8
):2921
–7
.
[PubMed]
0270-647456.
Haaf
M
, Leicht
G
, Curic
S
, Mulert
C
. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model
. Curr Pharm Biotechnol
. 2018
;19
(4
):293
–307
.
[PubMed]
1389-201057.
MacKay
MB
, Paylor
JW
, Wong
JT
, Winship
IR
, Baker
GB
, Dursun
SM
. Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics
. Front Psychiatry
. 2018
Oct
;9
:537
.
[PubMed]
1664-064058.
Plitman
E
, Nakajima
S
, de la Fuente-Sandoval
C
, Gerretsen
P
, Chakravarty
MM
, Kobylianskii
J
, et al. Glutamate-mediated excitotoxicity in schizophrenia: a review
. Eur Neuropsychopharmacol
. 2014
Oct
;24
(10
):1591
–605
.
[PubMed]
0924-977X59.
Hu
W
, MacDonald
ML
, Elswick
DE
, Sweet
RA
. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
. Ann N Y Acad Sci
. 2015
Mar
;1338
(1
):38
–57
.
[PubMed]
0077-892360.
Morris
RG
. Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5
. J Neurosci
. 1989
Sep
;9
(9
):3040
–57
. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2552039
[PubMed]
0270-647461.
Saykin
AJ
, Gur
RC
, Gur
RE
, Mozley
PD
, Mozley
LH
, Resnick
SM
, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning
. Arch Gen Psychiatry
. 1991
Jul
;48
(7
):618
–24
. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2069492
[PubMed]
0003-990X62.
Bilder
RM
, Goldman
RS
, Robinson
D
, Reiter
G
, Bell
L
, Bates
JA
, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates
. Am J Psychiatry
. 2000
Apr
;157
(4
):549
–59
.
[PubMed]
0002-953X63.
Luby
ED
, Gottlieb
JS
, Cohen
BD
, Rosenbaum
G
, Domino
EF
. Model psychoses and schizophrenia
. Am J Psychiatry
. 1962
Jul
;119
(1
):61
–7
.
[PubMed]
0002-953X64.
Domino
EF
, Luby
ED
. Phencyclidine/schizophrenia: one view toward the past, the other to the future
. Schizophr Bull
. 2012
Sep
;38
(5
):914
–9
.
[PubMed]
0586-761465.
Adler
CM
, Malhotra
AK
, Elman
I
, Goldberg
T
, Egan
M
, Pickar
D
, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia
. Am J Psychiatry
. 1999
Oct
;156
(10
):1646
–9
.
[PubMed]
0002-953X66.
Lorrain
DS
, Baccei
CS
, Bristow
LJ
, Anderson
JJ
, Varney
MA
. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
. Neuroscience
. 2003
;117
(3
):697
–706
. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12617973
[PubMed]
0306-452267.
Howes
O
, McCutcheon
R
, Stone
J
. Glutamate and dopamine in schizophrenia: an update for the 21st century
. J Psychopharmacol
. 2015
Feb
;29
(2
):97
–115
.
[PubMed]
0269-881168.
Docherty
NM
, St-Hilaire
A
, Aakre
JM
, Seghers
JP
. Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia
. Schizophr Bull
. 2009
May
;35
(3
):638
–45
.
[PubMed]
0586-761469.
Myin-Germeys
I
, van Os
J
. Stress-reactivity in psychosis: evidence for an affective pathway to psychosis
. Clin Psychol Rev
. 2007
May
;27
(4
):409
–24
.
[PubMed]
0272-735870.
Logan
AC
, Jacka
FN
. Nutritional psychiatry research: an emerging discipline and its intersection with global urbanization, environmental challenges and the evolutionary mismatch
. J Physiol Anthropol
. 2014
Jul
;33
(1
):22
.
[PubMed]
1880-679171.
Sarris
J
, Logan
AC
, Akbaraly
TN
, Amminger
GP
, Balanzá-Martínez
V
, Freeman
MP
, et al.; International Society for Nutritional Psychiatry Research
. Nutritional medicine as mainstream in psychiatry
. Lancet Psychiatry
. 2015
Mar
;2
(3
):271
–4
.
[PubMed]
2215-0366© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
